Allogene Therapeutics, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 28/100
What the filing says
On May 12, 2026, Allogene terminated its exclusive license agreement with Overland Therapeutics (originally dated December 14, 2020) covering cell therapy products that are no longer under active development. Concurrently, Allogene restructured its equity interest in Overland, reducing its shareholding from a higher level to 3% of the company's fully diluted share capital. Hillhouse remains the primary investor with protective board rights and veto powers so long as it holds ≥30% of converted Preferred Shares.
Why this rating
License termination is routine for inactive programs; equity reduction (~$184M co.) is immaterial in absolute dollars; no concrete financial impact quantified. Execution of strategic pivot, not forced.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.